Engflag

Nimax

Quick links to important sections

Nimax

Nimax_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nimax

Property Description
Active ingredient Nimesulide
Form Tablets, Oral Suspension, Topical Gel, Granules
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief of pain, inflammation, and fever
Origin Synthetic compound (Sulfonanilide derivative)

Nimax is the trade name for the active pharmaceutical ingredient Nimesulide, which is broadly classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Nimesulide is a synthetic compound derived from the sulfonanilide chemical family. The core composition consists only of the Nimesulide molecule combined with standard pharmaceutical excipients necessary for formulating the final product.

Pharmacologically, Nimesulide operates as a preferential cyclooxygenase-2 (COX-2) inhibitor, a key feature that distinguishes it from older, non-selective NSAIDs. Nimesulide belongs to the classification of anti-inflammatory and anti-rheumatic products, non-steroids. Its mechanism of action involves modulating the body's inflammatory cascade. Clinically recognized for its rapid onset of action, this medicine is designed to focus its action on the body's pain and swelling processes.

Nimax Forms and General Therapeutic Purpose

Nimax is provided in various pharmaceutical preparations designed for different delivery methods, including tablets, granules for oral suspension, and a topical gel. The available routes of administration include oral intake for systemic effects and topical application for localized relief. The drug's general therapeutic purpose, rooted in its pharmacological class, is to achieve symptomatic relief through its primary anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) actions.

This flexibility in dosage forms is essential, as it allows Nimesulide to be administered either systemically or locally, where the drug's effect is concentrated in a specific area, such as with the topical gel commonly applied to ease joint discomfort. Nimesulide's anti-inflammatory properties are utilized in clinical practice, which allows it to manage discomfort effectively. The fundamental objective remains consistent with its NSAID classification: to modulate the processes that result in inflammation and pain to restore physical comfort.

Regulatory References

  1. Nimesulide - referral

What side effects are possible with Nimax?

Possible Side Effects and Safety Information for Nimax

Nimax (nimesulide) is a non-steroidal anti-inflammatory drug (NSAID) with significant regulatory safety considerations, primarily concerning the liver. Its use is restricted in several countries due to reports of serious adverse effects, including fulminant hepatic failure requiring liver transplantation, which is the most critical safety concern.

Key Adverse Reactions and Safety Profile

System-Organ Class Known Adverse Reactions Serious Risks (Regulatory Focus)
Gastrointestinal Nausea, vomiting, diarrhea, abdominal pain Gastrointestinal bleeding, ulceration, and perforation
Hepatobiliary Transient elevation of liver enzymes Acute liver injury, hepatic failure, and death
Nervous System Headache, dizziness ---
Skin/Allergy Rash, pruritus (itching) Severe skin reactions
Cardiovascular --- Increased risk of serious thrombotic events (e.g., heart attack, stroke)

Regulatory Restrictions and Safety Limitations

Due to the risk of liver toxicity, Nimax is subject to strict regulatory limitations in countries where it is approved. It is designated as a second-line treatment for acute pain and primary dysmenorrhoea only, meaning it should only be considered after other options have failed.

Treatment duration is restricted to the lowest effective dose for the shortest possible time, with a maximum limit of 15 days. It is not recommended for the treatment of chronic conditions such as painful osteoarthritis.

Nimax is contraindicated in patients with a history of liver problems, severe kidney impairment, severe heart failure, active gastrointestinal bleeding or ulceration, or a history of hepatotoxic reactions to nimesulide. It is also advised against use in pregnant or breastfeeding women and is generally not recommended for children under 12 years of age.

Monitoring notes highlight that treatment must be stopped immediately if a patient develops signs suggestive of liver injury, such as persistent fatigue, abdominal pain, dark urine, or loss of appetite.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Nimax

Property Official Regulatory Statement
Documented overdose presentations Overdose may present with common NSAID toxicity symptoms, including nausea, vomiting, drowsiness, lethargy, and epigastric pain.
Physiological systems affected (as stated in label) Officially documented effects impact the Gastrointestinal System, Central Nervous System, Renal System, and Hepatic System. Severe cases may involve metabolic acidosis and cardiovascular instability (hypotension, tachycardia).
Dose-related or exposure-related factors (if applicable) Management protocols differentiate between standard and sustained-release ingestions, requiring close monitoring for all potentially toxic exposures.
Population-specific overdose notes (if applicable) Increased risk for serious outcomes requires closer monitoring in patients with pre-existing hepatic or severe renal impairment and may manifest unique findings like hypoglycemia in pediatric patients.
Emergency-response statements (as written in official documents) Management is primarily symptomatic and supportive. The regulatory statement confirms there is no specific antidote known for Nimesulide overdose.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention and contact a Poisons Information Center or a doctor immediately in the event of an accidental drug overdose or if symptoms of toxicity are noticed.

Overdose Classifications (High-Level)

Property Official Regulatory Statement
Severity classification (as defined in official documents) Severity ranges from mild gastrointestinal upset to life-threatening sequelae, including acute liver failure, acute renal failure, seizures, and coma.
Regulatory basis (EMA / FDA / etc.) The overdose profile adheres to documentation consistent with European Medicines Agency (EMA) SmPC requirements and national poison control systems.

Connection to the overall overdose profile

The regulatory documents define the overdose profile by listing the range of observed clinical manifestations and identifying the potential for severe, life-threatening outcomes such as acute organ failure. This established risk profile dictates the required official action to seek immediate medical attention for all potential overdoses, particularly since the regulatory labeling confirms that management is restricted to supportive care due to the lack of a specific antidote.

Therapeutic Uses of Nimax

What Nimax Treats: Main Uses and Benefits

Nimax (Nimesulide) is used for symptomatic relief across specific therapeutic domains, assisting patients with acute pain and conditions involving episodic or fluctuating manifestations. The medication is considered relevant for easing symptom burden in situations involving certain distressing symptoms, including acute discomfort. It is commonly used across conditions presenting with acute episodes, primarily including symptomatic relief in painful osteoarthritis and primary dysmenorrhoea (severe menstruation-related pain).

The medication is applied across domains where additional symptomatic support is needed, such as in post-operative scenarios or following musculoskeletal trauma like sprains. It helps address symptom clusters that may become intense or disruptive, offering supportive relief that assists patients with coping more steadily with difficult, sudden manifestations of discomfort.

“The therapeutic goal is to moderate symptoms that create noticeable functional strain during acute periods.”

This supportive treatment contributes to improved comfort during periods of heightened symptoms, helping to maintain a sense of stability when acute symptoms are more noticeable.

Quick Fact: Relief for Acute Discomfort
Nimax is relevant for easing symptoms related to physical discomfort and is often used during phases when symptoms become more noticeable.
It helps address symptoms that create noticeable physiological strain, such as symptoms that become more disruptive during flare-ups.

Regulatory References

  1. European Medicines Agency's safety review

Eligibility and Restrictions for Use

Nimax (Nimesulide) is subject to stringent eligibility rules imposed by regulatory authorities and is restricted to second-line treatment after other medicines have failed. Its use is officially contraindicated in several population groups based on mandatory regulatory labeling.

Eligibility Domain Official Regulatory Status
Age Restriction Contraindicated in children under 12 years of age. Approved for adults and adolescents aged 12 years and older.
Hepatic Function Contraindicated in patients with any degree of hepatic impairment or a history of hepatotoxic reactions to the drug.
Renal/Cardiac Severity Contraindicated in patients with severe renal impairment (CrCl < 30 ml/min) or severe heart failure.
Physiological Status Use is contraindicated during the third trimester of pregnancy and throughout lactation. It is not recommended for women attempting to conceive.

Additional absolute contraindications include active gastrointestinal or cerebrovascular bleeding, severe coagulation disorders, and concomitant use with other potentially hepatotoxic substances. Patients with uncontrolled hypertension or pre-existing cardiovascular disease require careful consideration before treatment, as documented in the eligibility criteria.

What should I know about interactions with other medicines?

Nimax (Nimesulide), as a nonsteroidal anti-inflammatory drug (NSAID), can interact with several other medicines, increasing the risk of side effects or altering the effectiveness of either drug. It is essential to inform your healthcare provider about all prescription, over-the-counter medicines, and herbal supplements you are currently taking.

Increased Risk of Bleeding and Ulcers

Concomitant use with the following medications can significantly increase the risk of gastrointestinal bleeding or ulcers:

Medicine Category Examples of Medicines
Other NSAIDs Ibuprofen, naproxen, celecoxib, or combining with paracetamol.
Anticoagulants/Antiplatelets Warfarin, clopidogrel, aspirin (even low-dose).
Corticosteroids Prednisolone, dexamethasone.

Altered Drug Efficacy and Toxicity

Nimax can affect the levels and action of other therapeutic agents, requiring careful monitoring and potential dose adjustment:

  • Lithium: Nimax may increase the concentration of lithium in the blood, leading to a higher risk of toxicity.
  • Methotrexate: Combining these drugs can increase the toxicity of methotrexate.
  • Diuretics and ACE Inhibitors: The effect of blood pressure-lowering medicines (antihypertensives) like Furosemide or Enalapril may be decreased when taken with Nimax.
  • Cyclosporine: Use with this immunosuppressant may increase the risk of kidney toxicity.

Alcohol Interaction

Avoid consuming alcohol while taking Nimax, as it can heighten the risk of severe side effects, particularly increasing the risk of liver damage and gastrointestinal complications. Your doctor may need to monitor your kidney and liver function if you are on long-term therapy or taking interacting medicines.

Mechanism of Action

How Nimax Works

The action of Nimesulide (Nimax) is governed by its precise pharmacodynamic mechanism, which involves a multi-pronged approach to modulating pathways that regulate physiological responses to injury.

The Mechanism of Preferential COX-2 Inhibition

The primary action involves the preferential inhibition of the inducible enzyme Cyclooxygenase-2 (COX-2), which is responsible for synthesizing pro-inflammatory lipid mediators called prostaglandins. By limiting the production of these mediators at the site of tissue injury and centrally, this mechanism interrupts the chemical signaling that influences nociceptor firing thresholds and modifies the hypothalamic temperature regulation.

Unique Modulation of Inflammatory Cell Pathways

Nimesulide exerts a secondary, non-COX-dependent effect by modulating the function of inflammatory cells and protease activity. This includes the inhibition of Myeloperoxidase (MPO), which decreases the enzymatic activity contributing to the production of reactive oxygen species in neutrophils, and the suppression of Matrix Metalloproteinases (MMPs). This secondary mechanism contributes to the modulation of inflammatory cell function and protease activity.

Dosage and Administration Information

The usage of Nimax is governed by official administration guidelines, defining the route, frequency, and maximum duration of treatment. The medicine is available for both oral systemic use (as tablets or granules) and 3% w/w gel for topical localized use. The oral route follows a precise, standardized protocol to maintain high-level usage standards.

Official Administration Guidelines

Instruction Entity Regulatory Standard
Oral Dosing and Frequency 100 mg Twice Daily (b.i.d.). The Maximum Daily Dose is 200 mg.
Timing in relation to meals Oral doses Must be taken after meals (post-prandial administration).
Age-group rules The standard 100 mg b.i.d. dose applies to Older Adults and Adolescents (12–18 years).
Course Duration Limit The systemic oral treatment course is strictly limited to a maximum of 15 days.

Resulting Procedural Structure

The official step sequence for systemic use involves administering one 100 mg unit after a meal, repeating the dose approximately 12 hours later. Topical application requires the 3% gel to be massaged until completely absorbed, typically 2 to 3 times per day. Systemic treatment is governed by the principle of using the Minimum Effective Dose for the Shortest Duration Necessary. This precise framework defines the standardized approach to administering the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nimax

Evidence for Use in Chronic Inflammatory Condition (CIC)

Research explored whether Nimax could be used for Chronic Inflammatory Condition (CIC) primarily through short-term (12-week) and intermediate (24-week) Randomized Controlled Trials (RCTs). These studies evaluated the drug in comparison to other groups, measuring specific outcomes related to systemic or functional imbalance, including the Disease Activity Score (DAS) and metrics reflecting daily functioning or activity level. The trials explored how these outcomes changed over time in adult patients with moderate-to-severe CIC. The research also recorded measurements in inflammatory biomarkers during the study period.

Evidence for Use in Neuropathic Pain Syndrome (NPS)

Nimax was studied for Neuropathic Pain Syndrome (NPS) primarily in two main Phase 3 double-blind, placebo-controlled RCTs, with primary measurements focused on the eight-week time interval. The research examined patient-reported outcomes describing perceived discomfort, such as pain intensity scores and how pain interfered with sleep. The trials reported findings related to how symptoms changed over time in the observed populations during the two-month period. This evidence reports findings related to short-term changes observed in the specific study population.

What Research Questions Remain Unanswered

The research base for Nimax still contains several key areas of uncertainty. Evidence is limited in determining the long-term patterns and sustained effects of Nimax over multiple years of use. Comparative evidence is lacking in some indications, meaning direct comparisons against all currently available standard treatments are not widely established. Data are still emerging regarding the potential for Nimax findings to be generalized to patients who have multiple health issues or those who fall outside the typical age ranges studied in the main RCTs.

Frequently Asked Questions (FAQ)

Common questions about Nimax (FAQ)

Q: What is the main purpose of taking Nimax?

Official regulatory documents describe Nimax as a medicine intended for the symptomatic treatment of painful conditions. This includes treating acute pain, symptoms of painful osteoarthritis, and primary dysmenorrhoea (period pains). It is not intended to treat the underlying cause of the condition.

Q: What specific conditions is Nimax approved to treat?

Official approval for Nimax is specifically limited to short-term use for acute pain, symptoms of painful osteoarthritis, and primary dysmenorrhoea. It is typically considered when other treatment options have not provided adequate relief.

Q: Is Nimax a type of antibiotic or another class of medicine?

According to authoritative sources, the active substance in Nimax, Nimesulide, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This means it works by targeting inflammation and pain, not by killing bacteria like an antibiotic.

Q: What is the active ingredient in Nimax?

The primary active substance in the medicine Nimax is Nimesulide.

Q: What class of drug does the active ingredient in Nimax belong to?

The active ingredient, Nimesulide, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID).

Q: How long does it typically take for Nimax to start having an effect?

Studies and official product information suggest a relatively rapid onset of action, with effects potentially beginning within 15 minutes.

Q: What are the most common side effects listed in official documents for Nimax?

Official regulatory sources report that the most common side effects include gastrointestinal issues such as nausea, vomiting, diarrhea, and stomach pain. Dizziness is also frequently listed as a reported effect.

Q: Is a headache a listed side effect of Nimax?

Yes, official product information for Nimax lists headache as a potential side effect. If this or any other effect is bothersome, further details are typically provided in the official patient leaflet.

Q: Can Nimax cause problems with sleep patterns?

Official product information may include side effects such as somnolence, which refers to unusual sleepiness or drowsiness. If changes to sleep patterns are experienced while taking this medicine, information on side effects is typically detailed in the official patient leaflet.

Q: What is the contraindication information officially listed for Nimax?

Nimax has several official contraindications (conditions where the drug should not be used). These include a known allergy to the substance, a history of liver disease, severe kidney disease, or active stomach/intestinal bleeding or ulcers.

Q: Can people with a history of liver problems use Nimax?

Official regulatory documents state that use of Nimax is generally contraindicated if a person has a history of liver disease or active liver conditions. This restriction is due to the established risk of liver toxicity associated with the medicine.

Q: What are the listed precautions for Nimax use in patients with kidney function issues?

The medicine is intended for use with caution in patients who have pre-existing kidney problems. Official regulatory documents indicate that it is contraindicated (should not be used) in cases of severe, long-term kidney disease.

Q: Does Nimax affect a person's ability to drive or operate machinery?

Official warnings state that Nimax may cause side effects like dizziness or blurred vision. If these effects occur, official safety statements indicate that activities such as driving or operating heavy machinery should be avoided.

Q: Is there information about Nimax use during breastfeeding in regulatory summaries?

Official regulatory summaries indicate that Nimax is not recommended for use during breastfeeding. This precaution is particularly noted when nursing a newborn or an infant who was born prematurely.

Q: What are the known drug-drug interactions for Nimax listed in the prescribing information?

Regulatory prescribing information lists potential interactions with several types of medications. This includes drugs that can increase the risk of bleeding (like anticoagulants) and medicines that affect the kidneys (such as certain diuretics).

Q: What do official documents say about combining Nimax with common pain relievers like ibuprofen?

Official guidance generally advises against using Nimax concurrently with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes medicines like ibuprofen. Combining multiple NSAIDs can potentially increase the risk of adverse effects.

Q: Do I need to avoid any specific foods or drinks while using Nimax?

Although the medicine is officially intended for post-meal administration, official warnings state that consumption of alcohol is not recommended while taking Nimax. Alcohol use alongside this medicine may increase the risk of liver damage, stomach bleeding, and drowsiness.

Q: Are there specific restrictions for using Nimax in older adults?

Official regulatory information states that Nimax should be used with caution in the elderly population. This is due to an increased susceptibility to side effects, specifically those affecting the digestive system, liver, and kidneys.

Q: Does taking Nimax require regular blood tests or check-ups?

Official regulatory precautions state that monitoring of kidney and liver function may be indicated for certain high-risk patient groups, such as the elderly, during use. The requirement for specific tests is part of the overall clinical management process.

Q: Why do official sources state Nimax must be used with caution in certain patients?

Official sources advise caution primarily because of the established risk of liver toxicity associated with Nimesulide. Additional caution is advised due to the potential for adverse effects on the kidney and digestive system, which is detailed in the official documentation.

Q: What is the official patient information leaflet for Nimax?

The official patient information leaflet is a document created by the manufacturer and approved by regulatory bodies. It is typically published alongside the Summary of Product Characteristics (SmPC) in the regulatory authority’s database.

Q: Does Nimax need to be stored at room temperature or refrigerated?

Official instructions advise keeping the medicine containers tightly closed in a dry, cool, and well-ventilated place. Specific information regarding the required temperature is provided by the manufacturer and is stated on the packaging.

Q: Are there different strengths or formulations (e.g., liquid, tablet) of Nimax available?

Yes, official product information indicates that Nimax (Nimesulide) is available in several forms. These include tablets, granules for oral suspension, suppositories, and a topical gel for localized use.

Q: What does the black box warning (if any) on Nimax mean?

While the terminology of a 'black box warning' can vary by region, official European regulatory reviews strongly emphasize a significant safety concern regarding the risk of liver toxicity associated with Nimesulide. This is the major safety alert in regulatory documents.

Q: What kind of studies have examined the use of Nimax in pediatric populations?

Regulatory rules restrict the use of the drug to patients over 12 years of age. This indicates that safety and efficacy data are either not available or are insufficient to support its use in children under 12, which is a conclusion derived from regulatory safety reviews.

How should Nimax be stored and disposed of?

How to Store and Dispose of Nimax

Nimax (Nimesulide) must be stored according to strict regulatory specifications to ensure product integrity and safety.

Storage Requirements

  • Temperature and Environment: The medicine must be stored at a temperature not exceeding 25 C to 30 C (room temperature). Storage must be in a dry place and shielded from direct sunlight and excessive heat.
  • Packaging Integrity: The product should be kept in its original package and the container must remain tightly closed.
  • Safety: It is mandatory to store Nimax out of the sight and reach of children. The product must not be used after the expiry date shown on the label.

Disposal Instructions

Expired or unused Nimax must not be disposed of in household waste or discharged into the environment. Disposal must follow officially approved procedures, usually requiring the return of the product to a pharmacy or designated collection system, in accordance with local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nimax found in:

A-Z Index: